In this randomized, double-blind, placebo-controlled crossover study, we investigated whether a peripheral nerve block could temporarily eliminate phantom and stump pain after amputation. Amputees with constant postamputation pain were included and randomized to receive a nerve block with lidocaine 2% with adrenaline or saline in a crossover design. Spontaneous phantom and stump pain and evoked responses were assessed at baseline and at fixed time-points until 120 minutes after lidocaine or saline injection. The primary outcome was the difference in absolute change between worst pain intensity, either phantom or stump pain, at baseline and at 30 minutes after lidocaine or saline injection. Twelve amputees were randomized and 9 patients were included in the analysis. The absolute change in median worst pain intensity between lidocaine and saline injection was 22.0 (interquartile range, 24.0 to 0.0) (n 5 9, P 5 0.12). Nine of 9 patients reported at least some pain relief after lidocaine injection compared with only 2 of 9 patients after saline injection (P 5 0.02). Phantom pain intensity was significantly reduced after lidocaine compared with saline injection (P 5 0.04), whereas there was no significant change in stump pain intensity between the 2 interventions (P 5 0.17). In all 9 amputees, evoked responses were eliminated after lidocaine injection. Thus, our findings suggest that afferent input from the peripheral nervous system plays an important role in postamputation pain.
Introduction
Both phantom pain (pain referred to the missing limb) and stump pain (pain in the residual limb) are frequent problems after amputations. Phantom pain affects a large proportion of amputees, with an incidence of 60% to 80%. 10 In most amputees, phantom pain is intermittent, and only few have constant pain. The frequency and intensity of phantom pain usually decrease over time, but some amputees continue to have severe, intractable, and disabling pain. 10, 20, 28 Stump pain is common in the early postoperative period but usually subsides with healing. In 5% to 10% of amputees, however, stump pain persists and may even get worse. 28 Chronic stump pain is often associated with sensory abnormalities such as hypoesthesia or hyperalgesia and allodynia. Postamputation phantom and stump pain are notoriously difficult to treat, and although a large range battery of different pharmacological and nonpharmacological treatment options have been proposed, no effective treatment has yet been found. 1 The severity of postamputation pain has prompted research into the responsible mechanisms, since an understanding of these will hopefully lead to improved treatment. Much literature in the last decades has focused on the role of cortical reorganization as an under-lying mechanism. 11, [14] [15] [16] [21] [22] [23] 25, 31, 38, 40 The unique ability of assessing functional and structural changes in the human brain in vivo may partly explain the focus on cortical reorganization. These changes, however, may be secondary to primary functional changes occurring at the site of injury in the peripheral nerves, 30 the dorsal root ganglia (DRG), 24, 37 and the spinal cord. 13 In fact, both experimental and clinical observations indicate that mechanisms in the periphery contribute to postamputation pain. Experimental studies have shown that a series of structural and biochemical changes take place following transection of nerve fibers, including formation of neuromas, upregulation of sodium channels, activation of mitogen-activated protein kinases, and altered gene expression, leading to hyperexcitability and spontaneous discharge. 5, 8, 29 Clinical observations suggest that regional nerve blocks can both trigger and relieve phantom pain. 3, 26, 27, 35, 37 Birbaumer et al. 3 showed that 3 of 6 patients with upper extremity amputations experienced a reduction in phantom pain after receiving an axillary brachial plexus blockade, and Vaso et al. 37 showed complete pain relief in 11 patients following intraforaminal blocks.
Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
With the use of peripheral nerve blocks, we have recently demonstrated that primary afferent input is critical for maintaining ongoing and evoked pain in other neuropathic pain conditions, including peripheral nerve injury pain, painful diabetic neuropathy, and poststroke pain. 17, 18 Prompted by our own research and the findings by others, we hypothesized that postamputation pain may be driven by an input from the peripheral nervous system, and that a peripheral nerve block can eliminate postamputation pain. We therefore performed a randomized, double-blind, placebo-controlled crossover trial with the goal of exploring the role of peripheral mechanisms of postamputation pain.
Materials and methods

Participants
The study was approved by the Regional Research Ethics Committee of Central Denmark (1-10-72-416-14) , the Danish Data Protection Agency (1-16-02-307-15) , and registered at clinicaltrials.gov (Identifier: NCT03317600). Written informed consent was obtained from all patients according to the Declaration of Helsinki. Patients were recruited from the Pain Clinic and the Departments of Orthopedic Surgery and Oncology, Aarhus University Hospital, Denmark, from September 2017 to January 2018. Patients were also recruited from "The Danish Patient Association for Amputees" and the Facebook group "Active Amputees in Denmark." Inclusion criteria were aged 18 years and older, amputation of an extremity or part of an extremity .6 months ago, and a constant ongoing phantom or stump pain intensity $3 on an 11-point numerical rating scale (NRS, 0 5 no pain and 10 5 worst imaginable pain) at the first intervention day and in the past week. Patients were excluded in case of insufficient language or communication skills, major cognitive or psychiatric disorder, treatment with warfarin or other anticoagulants as a contraindication for regional anesthesia, or allergy to local anesthetics. The study was performed at the Department of Anesthesiology and Intensive Care at Aarhus University Hospital, Aarhus, Denmark.
Study design, randomization, and blinding
The study was designed as a randomized, double-blind, placebo-controlled crossover trial. Each patient was scheduled for 3 visits: a screening visit and 2 intervention visits. At all visits, patients were required to have phantom or spontaneous stump pain of $3 on NRS 0 to 10. At the first intervention visit, patients were randomized to receive either a regional nerve block with 2% lidocaine solution with 1:200,000 epinephrine (active drug) or a regional nerve block with isotonic saline (placebo drug). After a washout period of minimum 7 days, the alternative study drug was given at the second intervention visit. The patient, the investigator, and the anesthetist were all blinded to the study drug injected at the given intervention visit.
Sealed envelopes were prepared for each patient containing information on which drug to be given at each of the 2 intervention visits, based on an online computer-generated randomization list. A study nurse, who was not otherwise involved in the study and had no contact with the patients or investigators, prepared 3 syringes of 10 mL (a total of 30 mL) lidocaine or isotonic saline for each patient. The syringes were marked with a patient identification number (ID) and a treatment visit number. The appearance of both types of study drug was identical, which made recognition impossible for both the patient, the investigator, and the anesthetist performing the nerve block.
Screening visit
After obtaining written informed consent, the following information was collected: cause, year, and localization of the amputation; type of pain (phantom pain, spontaneous stump pain, or both); average intensity of phantom and spontaneous stump pain during the past 7 days, the past 24 hours, and current pain intensity; and current analgesic treatment due to postamputation pain (patients were encouraged but not obligated to discontinue their analgesic treatment while participating in the trial). Patients also completed the Neuropathic Pain Symptom Inventory 6 with 12 questions about neuropathic pain characteristics. Before sensory testing, patients rated phantom and spontaneous stump pain. Worst spontaneous pain was defined as worst spontaneous pain in the phantom or in the stump-whichever was worst at the first intervention visit. Phantom sensations were rated on an 11-point scale, where 0 5 no phantom sensation and 10 5 most intense phantom sensation.
Evoked responses to cold (20˚C), warm (40˚C) (Rolltemp; Somedic AB, Hörby, Sweden), brush (SENSElab Brush-0.5; Somedic AB), and pinprick stimuli with a monofilament (Touch Test, 60 g; Stoelting, Co, Wood Dale, IL) were obtained by applying the stimuli proximally and towards the stump. Patients were asked to rate the sensation on a 25-0-5 scale (anchors: 25 5 no sensation, 0 5 normal sensation, 5 5 extremely intense sensation). Intensities of evoked phantom and/or evoked stump dysesthesia/ pain were rated on 2 separate 11-point scales (0 5 no dysesthesia/ no pain and 10 5 worst imaginable dysesthesia/worst imaginable pain). Areas of brush, warm, cold, pinprick hypoesthesia, and hyperesthesia were mapped. A nonpainful area on the contralateral limb was used as reference area. Wind-up ratio (WUR) was determined by a pinprick stimulus with a standardized intensity (512 mN). The stimuli were first applied individually and then in series of 10 stimuli with a frequency of 1 Hz within an area of 1 cm 2 . The intensity of the first stimulus and the last of the 10 stimuli were rated on the NRS (0-10), and the ratio between the 2 measures was calculated as WUR: a WUR of .1 indicated enhanced temporal summation. The pressure pain threshold (PPT) was determined by ascending stimuli intensity, applied as a slowly increasing ramp of 30 kPa/second (;0.5 kg/cm 2 s) with a handheld electronic pressure algometer with a 1-cm 2 probe area (Algometer; Somedic AB) at the area of spontaneous pain or at the area with most hyperesthesia/allodynia. A cutoff pressure value of 500 kPa was set for safety purposes. Examination of Tinel sign was performed by lightly tapping on the stump and was considered positive if the tapping elicited tingling or "pins and needles" in the distribution of the nerve, ie, evoked pain felt in the stump or in the phantom. All the described tests were performed by the same examiner (N.S.B.) and took place in a quiet room with a temperature of 22 to 23˚C with the patient lying relaxed in a comfortable position. WA) peripheral nerve block was performed with a 75-mm, 22-gauge insulated needle. An experienced regional anesthetist performed all nerve blocks with ultrasound-verified end point of perineural distribution of the study drug. This type of nerve block was chosen to provide adequate coverage of the painful area at the amputation site. Patients with lower extremity amputation below the knee received a popliteal sciatic block in combination with a femoral nerve block, and patients with above knee amputation received a sciatic nerve block in combination with a femoral nerve block. Patients with upper extremity amputation received an infraclavicular nerve block (finger, hand, below elbow, and above elbow amputations) or an interscalene brachial plexus block (shoulder disarticulation). The injected total volume was restricted to 25 mL (500 mg lidocaine). Nerve blocks were considered "potentially successful" if the nerve was visualized and if there was circumferential perineural spread of the study drug. Immediately after injection of the study drug and before any assessment of pain/sensory testing, the anesthetist who performed the nerve block assessed if it was potentially successful or possibly failed, based on the above criteria.
Assessment of spontaneous pain intensity and evoked responses after peripheral nerve block
Ratings of phantom pain, spontaneous stump pain, phantom sensations, and evoked responses to brush, cold, warm, and pinprick stimuli were recorded at fixed time-points (at 0 [baseline], 5, 10, 20, 30, 45, 60, 75, 90, 105, and 120 minutes) after the injection of the study drug. Thirty minutes after injection of the study drug, the following tests were repeated: mapping of areas with hypoesthesia and hyperesthesia and assessment of WUR, PPT, and Tinel sign. Patients were asked to rate whether they had experienced any pain relief of the nerve block on a 6-point scale ("worse pain," "no," "little," "moderate," "good," or "complete pain relief"). Patients with any pain relief were contacted the following day to obtain information about the time of return of their At the end of both intervention visits, the patient and the investigator were asked to evaluate whether they believed lidocaine or saline had been administered in the nerve block.
Pharmacokinetic sampling and analysis
At both intervention visits, blood samples for lidocaine concentration analysis were collected through a peripheral vein 45 minutes after injection of the study drug. Blood was collected in duplicates in 4-mL heparinized tubes and centrifuged at 20˚C for 10 minutes at 4000 rpm. Plasma was transferred to 1.5-mL cryotubes and stored at 280˚C until analysis. Lidocaine concentration in plasma was determined by chromatic analysis (UPLC-ESI-MS/MS). 19 
Adverse effects
The following regional anesthesia-specific side effects were assessed systematically from 0 to 120 minutes after the injection of study drug: pain at the site of the injection, local hemorrhage, dizziness, drowsiness, perioral numbness or tingling, and dry mouth. In addition, patients were encouraged to spontaneously report any other side effects/adverse advent. The timing of onset and resolution of all adverse effects was recorded.
Statistical analysis
We assumed that 90% of the patients would report a larger pain reduction after lidocaine injection compared with saline injection. With a sample size of 12 patients, a binomial test would achieve a power of 89% (and an actual significance level of 3.9%). The primary outcome was the difference in absolute change between the worst pain intensity at baseline and the pain intensity at 30 minutes after injection of lidocaine/saline (the worst pain intensity at the first intervention visit, phantom pain or spontaneous stump pain, was chosen for comparison at both intervention visits).
Wilcoxon signed-rank test was used for analysis and results presented as medians with interquartile range (IQR). Secondary outcomes were analyzed separately by Wilcoxon signed-rank test and included differences in patient-experienced pain relief 30 minutes after injection (dichotomized in "no pain relief/worse pain" or in "any pain relief"), and differences in phantom and spontaneous stump pain intensity (NRS: 0-10) at baseline and 30 Table 1 Demographic data and pain characteristics. minutes after injection of lidocaine/saline. Exploratory outcomes included differences in evoked sensation/pain at baseline and 30 minutes after injection, differences in areas with hyperesthesia and PPT and Tinel sign and WUR at baseline and 30 minutes after injection. Before data analysis and unblinding, it was decided only to include patients with a potentially successful nerve block in the analysis for primary and secondary outcomes. The specification of the time-point for the primary outcome was defined in a modified data analysis plan, which was completed and signed before data analysis and unblinding. Statistical analysis was performed with STATA release 12 (StataCorp, College Station, TX). 
Results
Patient characteristics
Sixty-two patients were assessed for eligibility. Twelve patients fulfilled the inclusion and exclusion criteria and were included, and 11 patients completed the study (Fig. 1) . Patient characteristics are listed in Table 1 . Eight of the 12 patients took analgesics and continued the use unchanged during the study period. Figure 2 shows a body map with the site of amputation and the distribution of phantom pain, spontaneous stump pain, and evoked stump 
The study drug given at the first intervention visit is marked with either L (lidocaine) or S (saline) next to the study ID. * Marks failed peripheral nerve block (#3 and #5). Scores marked with bold represent worst spontaneous pain before/after peripheral nerve block and were chosen based on the type of pain (stump/phantom) that were rated with the highest intensity at the first intervention day. Five patients reported stump pain, and 5 patients reported phantom pain as their worst spontaneous pain. Two patients, #8 and #11 (both finger amputations) were not able to differentiate between stump pain and phantom pain; hence, both stump pain and phantom pain are marked with bold. ID, identification number; NRS, numerical rating scale.
pain. At the screening and at both intervention visits, all patients presented with phantom pain or spontaneous stump pain $3 on the NRS, except one subject (#11) who presented with a worst spontaneous pain intensity of 2 on the NRS at the second intervention day (saline).
Peripheral nerve block
All patients underwent a peripheral nerve block at the first intervention day, but one patient (#8) withdrew consent before the second intervention visit. Twelve patients received a nerve block with lidocaine, and 11 patients received a nerve block with saline. Five patients (#6, #8, #10, #11, and #12) had an infraclavicular brachial plexus block, 1 patient (#4) an interscalene brachial plexus block, 2 patients (#2 and #9) a popliteal (tibial/peroneal) sciatic block in combination with a femoral nerve block, and 4 patients (#1, #3, #5, and #7) a sciatic nerve block in combination with a femoral nerve block. Two patients (#3 and #5) presented with very short amputation stumps and long-standing amputations. In both patients, the sciatic nerve was very difficult to visualize by ultrasound, which made the quality of the nerve block questionable. Based on the uncertainty of the quality of the nerve block, it was decided before unblinding and before analysis that the primary outcome should be calculated both with and without data on patients #3 and #5, and they were excluded from the statistical analysis for secondary outcomes. The decision on the quality of the nerve block was made exclusively by the anesthesiologist performing the nerve block immediately after the injection, and he was therefore blinded to the outcomes of spontaneous and evoked pain after injection of lidocaine/saline.
Primary outcome
Five patients reported spontaneous stump pain as their worst spontaneous pain, 5 patients reported phantom pain as their worst spontaneous pain, and 2 patients (#8 and #11), both with amputation of a finger, were not able to distinguish between spontaneous stump and phantom pain and rated them with equal intensity ( Table 2 
Secondary outcomes
The following results are reported for the 10 patients in whom the block was deemed successful; #3 and #5 were excluded, and for patient #8, only results for the intervention visit with lidocaine are included. Table 2 summarizes patient-reported pain relief 30 minutes after injection of lidocaine/saline and the individual changes in phantom and spontaneous stump pain from baseline to 30 minutes after injection. Nine of 9 patients reported at least some pain relief after nerve block with lidocaine compared with only 2 of 9 patients after saline injection (n 5 9, P 5 0.01) (Fig. 5) . . In 2 patients, spontaneous stump pain intensity decreased but was not eliminated after the nerve block with lidocaine, and both patients reported a sensation of tingling and pinching that resembled their usual spontaneous stump pain. Six patients reported phantom sensations at the intervention visit with lidocaine. Thirty minutes after the injection of lidocaine, one patient had a complete loss and 2 had a reduction of phantom sensations. The patients (#2, #6, and #11) who experienced a reduction or complete loss of phantom sensations also experienced pain relief. One patient (#4) had no change in phantom sensations but experienced some pain relief in phantom pain (from 5 to 3) 30 minutes after the injection. Five patients (#2, #4, #6, #7, and #11) had phantom sensations at the intervention visit with saline, and no changes in phantom sensations 30 minutes after nerve block with saline were reported. Table 3 presents changes in evoked responses. After lidocaine injection, pinprick hyperalgesia was abolished in 6 of 6 patients. The reverse was evident at the day of saline injection; here, 5 patients reported pinprick hyperalgesia at baseline, but 10 patients reported pinprick hyperalgesia 30 minutes after saline injection. Brush-, cold-and warm-evoked dysesthesia was abolished 30 minutes after lidocaine injection, but not 30 minutes after saline injection (Figs. 6-8 ). Pressure pain thresholds increased in 9 of 12 patients after lidocaine injection compared with 3 of 11 after saline injection. Tinel sign was eliminated in 6 of 8 patients after lidocaine injection, but after saline injection 8 of 8 continued to have a positive Tinel sign. All 5 patients with WUR .0 at baseline scored a WUR of 0 after lidocaine injection. Before saline injection, 3 patients had a WUR .1; 30 minutes after the injection, 8 had a WUR .1.
Assessment of blinding
Nine of 12 patients correctly identified lidocaine as the given intervention due to either pain relief and numbness (n 5 8) or numbness alone (n 5 1), and 7 of 11 patients correctly identified saline as the intervention given due to lack of pain relief (n 5 5) or because that they had a greater pain relief at the first intervention visit (lidocaine) (n 5 2). One patient could not identify the given treatment at any of the intervention visits, and 2 patients believed they had received lidocaine at both visits. The investigator correctly identified lidocaine as the given intervention in 10 of 12 patients after lidocaine injection and in 10 of 11 patients after saline injection.
Analysis of plasma concentration of lidocaine
Individual plasma concentrations for lidocaine varied from 0.28 mg/L to 1.8 mg/L, except in one patient (#2), in whom plasma lidocaine was 2.8 mg/L. Lidocaine plasma concentrations below 2 mg/L are considered unlikely to elicit a systemic analgesic effect. 18 As expected, lidocaine was detectable in plasma only at one of the treatment visits for all patients, except one (#5) who was using lidocaine patches for his stump pain and therefore exhibited detectable plasma concentrations for lidocaine at both intervention visits.
Adverse effects
One patient experienced a near-vasovagal syncope with bradycardia and hypotension during the needle placement at the first intervention visit but recovered fully after a few minutes. The patient was treated briefly with oxygen through nasal cannula but received no other medical treatment. Another patient (#8) experienced a loss of sensation and a worsening in pain immediately after the nerve block and therefore choose not to Figure 5 . Interindividual difference in pain relief 30 minutes after injection with lidocaine vs saline (n 5 9, patients #3, #5, and #8 excluded). Six-point scale on the y-axis is defined by "worse pain," "no pain relief," "some pain relief," "moderate pain relief," "good pain relief," and "complete pain relief." Table 3 Evoked responses and pain pressure thresholds before and 30 minutes after peripheral nerve block. 
Discussion
In this randomized, double-blind, placebo-controlled trial, we did not demonstrate a statistically significant reduction in worst spontaneous postamputation pain 30 minutes after a peripheral nerve block with lidocaine vs placebo. However, we did find a significant difference in patient-reported pain relief; all patients included in the analysis reported at least some pain relief, and 5 patients reported good or complete pain relief following lidocaine. By contrast, only 2 patients reported pain relief after saline injection. A separate analysis of changes in phantom and spontaneous stump pain revealed a significant reduction in phantom pain with the intervention. Evoked dysesthesia and pain, including pinprick hyperalgesia, Tinel sign, and WUR were completely eliminated in all patients after nerve block with lidocaine but not in any patients after saline injection. Taken together, the key study findings suggest that anesthetic peripheral nerve blocks did not abolish spontaneous postamputation pain in all study patients but gave significant patient-reported pain relief and relieved phantom pain, as well as abolished evoked pain, dysesthesia, and allodynia compared with the placebo intervention. Only very few other studies have examined the effect of nerve blocks in postamputation pain. In a small non-blinded and non-placebo-controlled study, Birbaumer et al. 3 found that 3 of 6 amputees receiving an axillary brachial plexus block had a complete elimination of phantom pain 20 minutes after injection, whereas the remaining 3 amputees did not obtain any pain reduction or relief. Changes in spontaneous stump pain or evoked responses were not reported. In the 3 patients with phantom pain relief, there was a substantial reduction of cortical reorganization. The authors concluded that there is a functional link between cortical reorganization and phantom limb pain in amputees; however, they did not define the causal nature of that relationship. 3 Vaso et al. in a nonblinded study found that phantom pain was completely eliminated or substantially reduced in 11 patients who received an intrathecal block (likely affecting signal transduction and transmission processes both in the DRG and the spinal cord) and in 25 of 28 patients receiving intraforaminal block (affecting the DRG). The authors concluded that their results were inconsistent with maladaptive cortical plasticity as a driver of phantom pain. A critical role of the peripheral nervous system for maintaining spontaneous pain has also been found in other neuropathic pain conditions. In an open-label study by Haroutounian et al., 18 patients with peripheral nerve injury (n 5 7) or bilateral distal polyneuropathy (n 5 7) had a complete and temporary relief of spontaneous pain after a peripheral nerve block. In another similar study, 6 of 7 patients with central poststroke pain also experienced a complete temporary pain relief after a peripheral nerve block at the extremity with chronic pain. 17 In agreement with Birbaumer et al., 3 we did not find a complete relief of postamputation pain in all patients and no significant difference with placebo on the overall outcome. It is possible that postamputation pain in some patients has important contributing mechanisms that originate more proximally to the damaged nerve endings (eg, in the DRG). It is also possible that it is explained partly by methodological aspects. For example, we cannot exclude the possibility that some smaller cutaneous nerves have not been anesthetized with the nerve block. We found a significant effect over placebo for phantom pain, and the results on overall postamputation pain could be biased by the fact that after the nerve block, some patients experienced a sensation of tingling or pinching in the stump that resembled their usual spontaneous stump pain. Finally, we saw a clearer difference using pain relief than pain intensity scales. A recent study has suggested that patient-reported pain relief is a more sensitive method than assessing a reduction in pain intensity. 12 Previous studies have shown that there is a strong correlation between the presence of phantom pain and spontaneous stump pain, 7,32-34 which may be interpreted as spontaneous stump and phantom pain sharing some of the same mechanisms. Surprisingly, only phantom pain intensity was significantly reduced. Baseline phantom pain intensity was higher than baseline spontaneous stump pain intensity at the intervention day with lidocaine, which may, together with the low number of patients in our study, explain the lack of significant spontaneous stump pain reduction.
In this study, lidocaine, a nonspecific sodium channel blocker was used to block the signal transduction from the peripheral nerves to the dorsal horn. After nerve injury, experimental studies have documented an enhanced expression of subtypes of voltage-sensitive sodium channels (ie, Na V 1.3, Na V 1.7, Na V 1.8, and Na V 1.9) over the axon, cell body, and dendrites. 36 These changes are believed to result in ectopic impulses and hyperexcitability of the axon and the DRG, 4, 9 which is very likely to play an important role in postamputation phantom and stump pain.
We acknowledge that our study has some limitations. Our findings are based on a small and heterogeneous population with different types of amputations and a mix of phantom and spontaneous stump pain, but recruitment of this group of patients is difficult because only few amputees have constant ongoing phantom/spontaneous stump pain .3, which is the inclusion criterion for this study. We excluded 3 patients due to either a failed nerve block or withdrawal of consent, which affected the study power for assessing the primary outcome. Blinding is difficult because the signs of a complete nerve block are easily recognizable. In addition, patients were not requested to discontinue their analgesic medications; although all participants had ongoing pain at baseline, a greater pain reduction could potentially have been shown if the patients at baseline have had a higher pain intensity score. It may be argued that the effect of the nerve block with lidocaine could be due to a systemic effect of lidocaine. However, except for one patient, the plasma lidocaine concentration was below 1.8 mg/L around the expected time for peak concentration 18 (at 45 minutes); these concentrations are unlikely to contribute to a systemic effect of lidocaine.
2,39
Conclusion
Despite the limitations, this is the first placebo-controlled doubleblind trial examining the effect of a peripheral nerve block in postamputation pain. We found a large and significant increase in pain relief and a reduction in phantom limb pain with the local anesthetic nerve block, as well as abolition of evoked pain, Tinel sign, wind-up, and mechanical allodynia, which were not observed with the placebo block.
Given more consistent relief of phantom and stump postamputation pain reported with the injection of local anesthetics in the proximity of DRG or the spinal cord, 37 it would be beneficial to perform further work in identifying critical mechanisms that contribute to pain on an individual level. A larger study where patients with postamputation pain receive successful regional blocks at different levels (ie, slightly proximal to the peripheral nerve injury, at the level of the DRG, and intrathecally) could help identify important mechanistic contributors to postamputation pain on the individual patient level.
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